Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain zaps tailored to you: new hope for PTSD?

NCT ID NCT07526285

Symptom relief Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a personalized form of brain stimulation (PrTMS) for PTSD in 100 military veterans. Unlike standard treatments, it uses an EEG brainwave test to customize the therapy to each person. Participants will receive either active treatment or a sham version over 6 weeks, and researchers will track changes in PTSD symptoms, mood, and sleep. The goal is to see if this tailored approach provides better and longer-lasting relief.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Jan 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Reserve or former member of the military (veteran status) * Age 18 years or older * Primary diagnosis of post-traumatic stress disorder (PTSD) confirmed by the - Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) * Post-Traumatic Stress Disorder Checklist for DSM-5 (PCL-5) score ≥ 33, indicating clinically significant PTSD symptoms * Proficient in English (spoken and written) to ensure understanding of study procedures and informed consent Exclusion Criteria: * History of open-skull traumatic brain injury * Clinically significant seizure disorder or history of manic episodes * Neurological conditions associated with increased risk (e.g., increased intracranial pressure, brain lesions, stroke, cerebral aneurysm) * Electroencephalogram (EEG) abnormalities suggesting elevated seizure risk * Repetitive transcranial magnetic stimulation (rTMS) within 3 months prior to screening * Current use of antipsychotic or anticonvulsant medications * Presence of intracranial implants or non-removable metal in or near the head (excluding the mouth) * Clinically significant or unstable medical conditions, including active suicidal ideation * Uncontrolled medical illness (e.g., thyroid, hepatic, cardiac, pulmonary, or renal disease) * Initiation of PTSD-specific treatment within the past 4 weeks (participants on a stable regimen may be eligible) * Pregnancy (for women of childbearing potential) * Any condition that, in the opinion of the investigator, may interfere with study participation or completion

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Posttraumatic stress disorder (PTSD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

post-traumatic stress disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Posttraumatic stress disorder (PTSD)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Home Base

    Charlestown, Massachusetts, 02129, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.